Had this been the only piece to precede the Mahler, the connection between this acknowledgement of country and Mahler’s ...

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs ...

On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the ...

Putting Gershwin up against Mahler is a challenge, but Simone Young and Jean-Yves Thibaudet bring it off in the Sydney Symphony's 2026 season opener.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025.

Financial guidance assumes a standard FDA review for olezarsen with a Q4 approval, though management notes that a priority ...

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +5.39% and +30.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the ...

Mahler’s Song of the Earth begins with wild craggy upward striving phrases from the tenor, and ends with the mezzo-soprano subsiding in gentle steps of transcendent acceptance – ewig... ewig ...

Hougen projected 2026 revenue in the range of $800 million to $825 million, “this represents an increase of approximately 20% over last year after adjusting for the onetime $280 million Sapablursen ...

Ionis Pharmaceuticals reports fourth-quarter results before the bell Wednesday, as the RNA-targeted drug developer navigates a pivotal shift from research partner to commercial-stage biotech. Analysts ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...